Hypolipoproteinemia causes: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 112: Line 112:


====Low HDL Causes====
====Low HDL Causes====
{{col-begin|width=80%}}
{{col-break|width=33%}}
*[[Anabolic steroids]]<ref name="pmid20816133">{{cite journal| author=Achar S, Rostamian A, Narayan SM| title=Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. | journal=Am J Cardiol | year= 2010 | volume= 106 | issue= 6 | pages= 893-901 | pmid=20816133 | doi=10.1016/j.amjcard.2010.05.013 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20816133 }} </ref>
*[[Androgens]]
*Apo A-1 Giessen
*Apo A-1 Marburg
*[[Apo A-1 Milano]]
*Apo A-1 Munster
*[[apolipoprotein C2|Apolipoprotein C-11 deficiency]]<ref name="BaggioManzato1986">{{cite journal|last1=Baggio|first1=G|last2=Manzato|first2=E|last3=Gabelli|first3=C|last4=Fellin|first4=R|last5=Martini|first5=S|last6=Enzi|first6=G B|last7=Verlato|first7=F|last8=Baiocchi|first8=M R|last9=Sprecher|first9=D L|last10=Kashyap|first10=M L|title=Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.|journal=Journal of Clinical Investigation|volume=77|issue=2|year=1986|pages=520–527|issn=0021-9738|doi=10.1172/JCI112332}}</ref>
*[[atazanavir|Atazanavir sulfate]]
*[[Atenolol]]
*[[Bendrofluazide]]
*[[Benzodiazepines]]
*[[Beta blockers]]
*[[Chronic renal failure]]
*Dysglobulinemia<ref name="pmid2366654">{{cite journal| author=Cuisinier-Raynal JC, Bire F, Clerc M, Bernard J, Sarrouy J| title=[Human malaria: dysglobulinemia-hypocholesterolemia syndrome]. | journal=Med Trop (Mars) | year= 1990 | volume= 50 | issue= 1 | pages= 91-5 | pmid=2366654 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2366654 }} </ref>
*[[cholesterylester transfer protein|Elevated cholesterylester transfer protein (CETP) activity]]
*[[hepatic lipase|Elevated hepatic triglyceride lipase activity]]
*[[End-stage renal disease]]
*[[familial hypoalphalipoproteinemia|Familial Apo A-1 deficiency]]
*Familial combined hypolipidemia<ref name="pmid20942659">{{cite journal| author=Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C et al.| title=Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. | journal=N Engl J Med | year= 2010 | volume= 363 | issue= 23 | pages= 2220-7 | pmid=20942659 | doi=10.1056/NEJMoa1002926 | pmc=PMC3008575 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20942659 }} </ref>
*Familial deficiency of Apo A-1 and Apo C-III<ref name="pmid3934306">{{cite journal| author=Schaefer EJ, Ordovas JM, Law SW, Ghiselli G, Kashyap ML, Srivastava LS et al.| title=Familial apolipoprotein A-I and C-III deficiency, variant II. | journal=J Lipid Res | year= 1985 | volume= 26 | issue= 9 | pages= 1089-101 | pmid=3934306 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3934306 }} </ref>
*[[Familial HDL deficiency]]
*[[Familial hypertriglyceridaemia]]
*[[Familial hypoalphalipoproteinemia]]
*[[lecithin cholesterol acyltransferase deficiency|Familial lecithin cholesterol acyltransferase (LCAT) deficiency]]
*[[Familial mixed hyperlipidaemia]]
*[[fish eye disease|Fish eye disease (partial LCAT deficiency)]]
*[[gammopathy|Gammopathies]]
{{col-break|width=33%}}
*[[carbohydrate|High carbohydrate diet]]
*[[triglyceride|High triglyceride]]
*[[Hydrochlorothiazide]]
*[[Insulin resistance]]
*[[LDL receptor deficiency]]
*[[Lipoprotein lipase deficiency]]
*[[Lopinavir]]
*[[Malabsorption]]
*[[Malnutrition]]
*[[Metabolic syndrome]]<ref name="pmid14742767">{{cite journal| author=Ito MK| title=The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin. | journal=Ann Pharmacother | year= 2004 | volume= 38 | issue= 2 | pages= 277-85 | pmid=14742767 | doi=10.1345/aph.1D218 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14742767 }} </ref>
*[[Nephrotic syndrome]]
*[[Niemann-Pick disease|Niemann-Pick disease type B]]
*[[Obesity]]<ref name="AshenBlumenthal2005">{{cite journal|last1=Ashen|first1=M. Dominique|last2=Blumenthal|first2=Roger S.|title=Low HDL Cholesterol Levels|journal=New England Journal of Medicine|volume=353|issue=12|year=2005|pages=1252–1260|issn=0028-4793|doi=10.1056/NEJMcp044370}}</ref>
*[[Physical inactivity]]<ref name="AshenBlumenthal2005">{{cite journal|last1=Ashen|first1=M. Dominique|last2=Blumenthal|first2=Roger S.|title=Low HDL Cholesterol Levels|journal=New England Journal of Medicine|volume=353|issue=12|year=2005|pages=1252–1260|issn=0028-4793|doi=10.1056/NEJMcp044370}}</ref>
*[[Probucol]] <ref name="pmid19457483">{{cite journal| author=Yamashita S, Matsuzawa Y| title=Where are we with probucol: a new life for an old drug? | journal=Atherosclerosis | year= 2009 | volume= 207 | issue= 1 | pages= 16-23 | pmid=19457483 | doi=10.1016/j.atherosclerosis.2009.04.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19457483 }} </ref>
*[[Progestins]]
*[[Propranolol]]
*[[reaven syndrome|Reaven syndrome X]]
*[[inflammatory disease|Severe inflammatory disease]]
*[[Severe liver disease]]
*[[Smoking]]<ref name="AshenBlumenthal2005">{{cite journal|last1=Ashen|first1=M. Dominique|last2=Blumenthal|first2=Roger S.|title=Low HDL Cholesterol Levels|journal=New England Journal of Medicine|volume=353|issue=12|year=2005|pages=1252–1260|issn=0028-4793|doi=10.1056/NEJMcp044370}}</ref>
*[[Sphingomyelinase deficiency]]
*[[Tangier disease]]
*[[Thiazide diuretics]]
*[[Tibolone]]
*[[diabetes mellitus|Uncontrolled diabetes mellitus]] <ref name="pmid15265253">{{cite journal| author=Miller M, Dobs A, Yuan Z, Battisti WP, Borisute H, Palmisano J| title=Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. | journal=Curr Med Res Opin | year= 2004 | volume= 20 | issue= 7 | pages= 1087-94 | pmid=15265253 | doi=10.1185/030079904125004105 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15265253}}</ref>
*[[low-fat diet|Very low-fat diet]]
{{col-end}}


====Low IDL Causes====
====Low IDL Causes====

Revision as of 14:06, 25 November 2013

Lipid Disorders Main Page

Overview

Causes

Classification

Abetalipoproteinemia
Hypobetalipoproteinemia
Familial hypoalphalipoproteinemia
LCAT Deficiency
Chylomicron retention disease
Tangier disease
Familial combined hypolipidemia

Differential Diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2]

Overview

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Causes Based on Major Lipoprotein Detected in Blood Laboratory Test

Low Cholesterol Causes

Low Chylomicron Causes

Low Chylomicron remnant Causes

Low Triglyceride Causes

Low HDL Causes

Low IDL Causes

Low LDL Causes

Low VLDL Causes

Combined List of Causes in Alphabetical Order

References

  1. ↑ 1.0 1.1 Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M; et al. (1992). "Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia". Science. 258 (5084): 999–1001. PMID 1439810.
  2. ↑ 2.0 2.1 Weintraub M, Grosskopf I, Trostanesky Y, Charach G, Rubinstein A, Stern N (1999). "Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism". J Clin Endocrinol Metab. 84 (7): 2532–6. PMID 10404832.
  3. ↑ Scanu, AM.; Aggerbeck, LP.; Kruski, AW.; Lim, CT.; Kayden, HJ. (1974). "A study of the abnormal lipoproteins in abetalipoproteinemia". J Clin Invest. 53 (2): 440–53. doi:10.1172/JCI107578. PMID 11344558. Unknown parameter |month= ignored (help)
  4. ↑ Welty, FK.; Mittleman, MA.; Wilson, PW.; Sutherland, PA.; Matheney, TH.; Lipinska, I.; Muller, JE.; Levy, D.; Tofler, GH. (1997). "Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population". Circulation. 95 (4): 825–30. PMID 9054738. Unknown parameter |month= ignored (help)
  5. ↑ Tassiopoulos T, Stamatelos G, Zakopoulos N, Fessas P, Eliopoulos GD (1995). "Low incidence of acute myocardial infarction in beta-thalassaemia trait carriers". Haematologia (Budap). 26 (4): 199–203. PMID 7590514.
  6. ↑ Maioli M, Pettinato S, Cherchi GM, Giraudi D, Pacifico A, Pupita G; et al. (1989). "Plasma lipids in beta-thalassemia minor". Atherosclerosis. 75 (2–3): 245–8. PMID 2712866.
  7. ↑ Pandolfino J, Hakimian D, Rademaker AW, Tallman MS (1997). "Hypocholesterolemia in hairy cell leukemia: a marker for proliferative activity". Am J Hematol. 55 (3): 129–33. PMID 9256291.
  8. ↑ Harris WS, Muzio F (1993). "Fish oil reduces postprandial triglyceride concentrations without accelerating lipid-emulsion removal rates". Am J Clin Nutr. 58 (1): 68–74. PMID 8317392.
  9. ↑ Harris WS, Hustvedt BE, Hagen E, Green MH, Lu G, Drevon CA (1997). "N-3 fatty acids and chylomicron metabolism in the rat". J Lipid Res. 38 (3): 503–15. PMID 9101431.
  10. ↑ 10.0 10.1 10.2 Iannello S, Cavaleri A, Milazzo P, Cantarella S, Belfiore F (2003). "Low fasting serum triglyceride level as a precocious marker of autoimmune disorders". MedGenMed. 5 (3): 20. PMID 14600656.
  11. ↑ Achar S, Rostamian A, Narayan SM (2010). "Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm". Am J Cardiol. 106 (6): 893–901. doi:10.1016/j.amjcard.2010.05.013. PMID 20816133.
  12. ↑ Baggio, G; Manzato, E; Gabelli, C; Fellin, R; Martini, S; Enzi, G B; Verlato, F; Baiocchi, M R; Sprecher, D L; Kashyap, M L (1986). "Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients". Journal of Clinical Investigation. 77 (2): 520–527. doi:10.1172/JCI112332. ISSN 0021-9738.
  13. ↑ Cuisinier-Raynal JC, Bire F, Clerc M, Bernard J, Sarrouy J (1990). "[Human malaria: dysglobulinemia-hypocholesterolemia syndrome]". Med Trop (Mars). 50 (1): 91–5. PMID 2366654.
  14. ↑ Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C; et al. (2010). "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia". N Engl J Med. 363 (23): 2220–7. doi:10.1056/NEJMoa1002926. PMC 3008575. PMID 20942659.
  15. ↑ Schaefer EJ, Ordovas JM, Law SW, Ghiselli G, Kashyap ML, Srivastava LS; et al. (1985). "Familial apolipoprotein A-I and C-III deficiency, variant II". J Lipid Res. 26 (9): 1089–101. PMID 3934306.
  16. ↑ Ito MK (2004). "The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin". Ann Pharmacother. 38 (2): 277–85. doi:10.1345/aph.1D218. PMID 14742767.
  17. ↑ 17.0 17.1 17.2 Ashen, M. Dominique; Blumenthal, Roger S. (2005). "Low HDL Cholesterol Levels". New England Journal of Medicine. 353 (12): 1252–1260. doi:10.1056/NEJMcp044370. ISSN 0028-4793.
  18. ↑ Yamashita S, Matsuzawa Y (2009). "Where are we with probucol: a new life for an old drug?". Atherosclerosis. 207 (1): 16–23. doi:10.1016/j.atherosclerosis.2009.04.002. PMID 19457483.
  19. ↑ Miller M, Dobs A, Yuan Z, Battisti WP, Borisute H, Palmisano J (2004). "Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C". Curr Med Res Opin. 20 (7): 1087–94. doi:10.1185/030079904125004105. PMID 15265253.
Retrieved from "https://www.wikidoc.org/index.php?title=Hypolipoproteinemia_causes&oldid=914900"